An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC

Physician Summary:

Nogapendekin Alfa Inbakicept-pmln

• Mechanism of Action: Nogapendekin alfa is an immunotherapy that combines a recombinant protein designed to stimulate the immune system with the aim of inducing a localized immune response against bladder cancer cells, particularly for carcinoma in situ and papillary tumors. It acts by enhancing the body’s immune response to cancer cells, stimulating an inflammatory response that targets the tumor. This approach helps activate the immune system without requiring systemic exposure.
• Administration: Nogapendekin alfa is administered intravesically, with patients typically receiving the therapy directly into the bladder via catheter. After intravesical administration, it is followed by a course of intravesical BCG therapy, which further primes the immune response and increases efficacy by maintaining bladder immunity over time.

This combination approach offers a novel, dual immunotherapeutic strategy for BCG-unresponsive NMIBC, potentially enhancing both local and systemic immune responses to bladder cancer.